COLOMBO NICOLETTA

Monk, B., Colombo, N., Tewari, K., Tekin, C., Keefe, S., Lorusso, D. (2024). Reply to P.-H. Luo et al. JOURNAL OF CLINICAL ONCOLOGY [10.1200/JCO.24.00077]. Detail

Boidot, R., Blum, M., Wissler, M., Gottin, C., Ruzicka, J., Chevrier, S., et al. (2024). Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer. EUROPEAN JOURNAL OF CANCER, 202(May 2024) [10.1016/j.ejca.2024.113978]. Detail

Tewari, K., Colombo, N., Monk, B., Dubot, C., Caceres, M., Hasegawa, K., et al. (2024). Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA ONCOLOGY, 10(2), 185-192 [10.1001/jamaoncol.2023.5410]. Detail

Caldarelli, M., Rezzi, S., Colombo, N., Pirali, T., Papeo, G. (2024). Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins. JOURNAL OF ORGANIC CHEMISTRY, 89(1), 633-643 [10.1021/acs.joc.3c02386]. Detail

Oaknin, A., Gladieff, L., Martínez-García, J., Villacampa, G., Takekuma, M., De Giorgi, U., et al. (2024). Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. THE LANCET, 403(10421 (6–12 January 2024)), 31-43 [10.1016/S0140-6736(23)02405-4]. Detail